Vismodegib in the treatment of advanced BCC

Hdl Handle:
http://hdl.handle.net/10147/324650
Title:
Vismodegib in the treatment of advanced BCC
Authors:
O’Kane, GM; Lyons, T; McDonald, I; Mulligan, N; Moloney, FJ; Murray, D; Kelly, CM
Citation:
O'Kane GM et al. Vismodegib in the treatment of advanced BCC. IMJ. 2014 107(7)
Publisher:
Irish Medical Journal
Journal:
Irish Medical Journal
Issue Date:
Jul-2014
URI:
http://hdl.handle.net/10147/324650
Abstract:
Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80%of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCCâ s. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedgefi, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.
Item Type:
Article
Language:
en
Keywords:
SKIN CANCER

Full metadata record

DC FieldValue Language
dc.contributor.authorO’Kane, GMen_GB
dc.contributor.authorLyons, Ten_GB
dc.contributor.authorMcDonald, Ien_GB
dc.contributor.authorMulligan, Nen_GB
dc.contributor.authorMoloney, FJen_GB
dc.contributor.authorMurray, Den_GB
dc.contributor.authorKelly, CMen_GB
dc.date.accessioned2014-08-11T13:28:49Z-
dc.date.available2014-08-11T13:28:49Z-
dc.date.issued2014-07-
dc.identifier.citationO'Kane GM et al. Vismodegib in the treatment of advanced BCC. IMJ. 2014 107(7)en_GB
dc.identifier.urihttp://hdl.handle.net/10147/324650-
dc.description.abstractBasal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80%of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCCâ s. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedgefi, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.en_GB
dc.language.isoenen
dc.publisherIrish Medical Journalen_GB
dc.subjectSKIN CANCERen_GB
dc.titleVismodegib in the treatment of advanced BCCen_GB
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.